[A new serological diagnostic method for malignant ovarian tumors of germ cell origin. Detection of antibodies to large glycopeptides isolated from F9 cells].
Whether the presence of antibodies in patients sera to large glycopeptides (LGP) isolated from a murine teratocarcinoma cell line (F9) can be useful in diagnosing malignant ovarian tumors of germ cell origin was examined by Farr's assay. We measured the binding ability to LGP by Farr's assay of human sera from 188 patients with various ovarian tumors and 110 normal volunteers. All of the 9 patients with dysgerminoma showed negative results (less than 200 cpm). Except the cases with dysgerminoma, 9 (64%) of the 14 patients with malignant ovarian tumors of germ cell origin were found positive (more than 200 cpm). Of these 9 positive cases, 4 cases with endodermal sinus tumor (EST), 2 cases with immature teratoma, one each with immature teratoma plus EST, choriocarcinoma, and mature solid teratoma were included. In contrast, all of the sera from benign ovarian tumors (111 cases), other malignant ovarian tumors (54 cases) and normal nonpregnant women (110 cases) were found negative. These result indicated that Farr's assay of anti-LGP antibodies in sera is useful in diagnosing ovarian germ cell tumors.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis*; D002478:Cells, Cultured; D004407:Dysgerminoma / Q000175:diagnosis*; D005260:Female; D006020:Glycopeptides / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D051379:Mice; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D013724:Teratoma / Q000276:immunology
D000912:Antibodies, Neoplasm; D006020:Glycopeptides